bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
184 hedge funds and large institutions have $457M invested in bluebird bio in 2022 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 64 increasing their positions, 46 reducing their positions, and 19 closing their positions.
132% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 19
73% more call options, than puts
Call options by funds: $8.46M | Put options by funds: $4.89M
39% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 46
14% more funds holding
Funds holding: 162 → 184 (+22)
9% more capital invested
Capital invested by funds: $419M → $457M (+$38M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.15% less ownership
Funds ownership: 4.25% → 4.1% (-0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.51M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.84M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$5.09M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.42M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$12M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$8.49M |
| 3 |
Millennium Management
New York
|
-$6.51M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$4.99M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.91M |
BLUE Hedge Fund Activity: Q4 2022 in Review
184 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2022, worth a combined $457M — up 9.1% from $419M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new BLUE positions and 19 closed out — a net gain of 25 holders — while 64 added to existing stakes and 46 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $8.51M. The largest seller was Tang Capital Management, cutting an estimated $12M.
- 184 institutional investors held bluebird bio (BLUE) as of Q4 2022, up from 162 in Q3 2022.
- Funds reported $457M of bluebird bio stock for Q4 2022, up 9.1% quarter-over-quarter.
- 44 funds opened new bluebird bio positions in Q4 2022 and 19 closed out, a net change of +25 holders.
- The largest bluebird bio buyer in Q4 2022 was Point72 Asset Management, an estimated $8.51M added.
- The largest bluebird bio seller in Q4 2022 was Tang Capital Management, an estimated $12M sold.
Based on aggregated 13F filings for Q4 2022.